Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
Top Cited Papers
- 20 June 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (18), 2607-2615
- https://doi.org/10.1200/jco.2006.09.2551
Abstract
Purpose: There are a large number of randomized controlled trials involving chemotherapy in the management of advanced pancreatic cancer. Several chemotherapeutic agents, either alone or in combination with other chemotherapy or novel agents, have been used. The aim of these meta-analyses was to examine the different therapeutic approaches, and the comparisons examined were as follows: chemotherapy versus best supportive care; fluorouracil (FU) versus FU combination chemotherapy; gemcitabine versus FU; and gemcitabine versus gemcitabine combination chemotherapy. Methods: Relevant trials were identified by searching databases, trial registers, and conference proceedings. The primary end point was overall survival. Results: One hundred thirteen randomized controlled trials were identified, of which 51 trials involving 9,970 patients met the inclusion criteria. Chemotherapy improved survival compared with best supportive care (hazard ratio [HR] = 0.64; 95% CI, 0.42 to 0.98). FU-based combination chemotherapy did not result in better overall survival compared with FU alone (HR = 0.94; 95% CI, 0.82 to 1.08). There was insufficient evidence of a survival difference between gemcitabine and FU, but the wide CI includes clinically important differences in both directions, making a clear conclusion difficult (HR = 0.75; 95% CI, 0.42 to 1.31). Survival was improved after gemcitabine combination chemotherapy compared with gemcitabine alone (HR = 0.91; 95% CI, 0.85 to 0.97). Conclusion: There was a significant survival benefit for chemotherapy over best supportive care and gemcitabine combinations over gemcitabine alone. This supports the use of gemcitabine-based combination chemotherapy in the treatment of advanced pancreatic cancer.Keywords
This publication has 70 references indexed in Scilit:
- Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine aloneChinese Journal of Digestive Diseases, 2006
- It’s What’s Inside That CountsJournal of Clinical Oncology, 2003
- A Systematic Overview of Chemotherapy Effects in Pancreatic CancerActa Oncologica, 2001
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- No standard treatment is available for advanced pancreatic cancerEuropean Journal of Cancer, 1995
- Chemotherapy prolongs survival in inoperable pancreatic carcinomaBritish Journal of Surgery, 1994
- Comparison of 5-Fluorouracil, Doxorubicin and Mitomycin C with 5-Fluorouracil Alone in the Treatment of Pancreatic-Biliary CarcinomasOncology, 1994
- Meta-Analyses of Randomized Controlled TrialsThe New England Journal of Medicine, 1987
- Treatment of Unresectable Pancreatic Carcinoma with 5-Fluorouracil, Vincristine, and CCNUScandinavian Journal of Gastroenterology, 1983
- A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancerCancer, 1974